Asymmetric Dimethylarginine Level in Children Undergoing Bone Marrow Transplantation
Dina Maher Ahmad
Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Eslam E. Elhawary
Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Gamal Alden Fathy
Hematology and Bone Marrow Transplant Department, Nasser Institute for Research and Treatment, Cairo, Egypt.
Hala Mohamed Nagy
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Ibrahim Mohamed Bedraya
Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mohamed Ramadan Elshanshory
Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Background: Asymmetric dimethylarginine (ADMA) is a toxic, non‐proteinogenic amino acids formed by post‐translational modification and is a uremic toxin that inhibits nitric oxide (NO) production. The aim of this work was to assess the serum level of asymmetric dimethylarginine in children underwent bone marrow transplantation.
Methods: This prospective, randomized controlled study has been conducted on 20 children aged 2-18 years underwent bone marrow transplantation (Group I) and 20 healthy control children of matched age and sex (group II).
Results: The serum level of ADMA was significantly higher after bone marrow transplantation (p value <0.05).
Conclusions: Elevated ADMA level after bone marrow transplantation indicates that endothelial dysfunction is a main complication in those patients.
Keywords: Asymmetric dimethylarginine, bone marrow transplantation